Skip to content
Pipeline

Therapeutic Candidates

Human Health
Programs
Early Discovery E Disc
Late Discovery L Disc
Lead Optimization L Opt
IND-Enabling IND
Clinical Clin
Human Health Oncology
Programs: 101
Programs: Endostatin E4
Solid Tumors
Programs: Target 3
Immuno-Oncology
Programs: Target 4
Immuno-Oncology
Programs: Target 5
Immuno-Oncology
Programs: EGFRvIII
Immuno-Oncology*
Programs: CCR8
Immuno-Oncology*
Programs: Target 8
Immuno-Oncology*
Programs: Target 9
Immuno-Oncology*
Human Health Autoimmune
Programs: PD-1
Autoimmune Diseases*
Human Health Fibrotic Diseases
Programs: 100

* Developed Using RubrYc Therapeutics’ Artificial Intelligence Discovery Engine

Recent advances in immunotherapies for oncology hold great promise in areas of high unmet medical needs. From our Drug Discovery Center in San Diego, we are deploying our AI Drug Discovery Platform to develop a robust immuno-oncology pipeline. IBIO-101, an IL-2 sparing anti-CD25 antibody, has demonstrated strong anti-tumor responses in pre-clinical models of disease, and we anticipate filing an investigational new drug application for this candidate.

We have seven other immuno-oncology candidates in our pipeline, along with a PD-1 agonistic mAb intended to treat serious autoimmune disorders.

Top